News|Articles|November 4, 2024
Best Practices, Strategies & Use of Novel Biological Responses for Robust Cell-Based Potency Assays (Executive Summary)
Author(s)Catalent
Cell-based assays (CBAs) are key tools for evaluating the potency of new biologic drugs. Catalent’s transcription-based bioassay simplifies and empowers the testing of new biologics.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Applying Analytical Quality by Design Principles to Biopharma Method Development and Optimization
2
CPHI Frankfurt 2025 Highlights Global Pharma Innovation and Manufacturing Leadership
3
Why Radiopharmaceuticals Are Ideal for Treating Cancer
4
Check Your Knowledge: Patient-Centric Care Through Oral Liquid Delivery
5
